Outcomes of ABO-incompatible liver transplantation in end-stage liver disease patients co-infected with hepatitis B and human immunodeficiency virus

Tang, Jian-Xin1,2; Zhang, Kang-Jun1,2; Fang, Tai-Shi1,2; Weng, Rui-Hui3; Liang, Zi-Ming1,2; Yan, Xu1,2; Jin, Xin1,2; Xie, Lin-Jie1,2; Zeng, Xin-Chen1,2; Zhao, Dong1,2,4,5,6,7

2023-03-21

10.3748/wjg.v29.i11.1745

WORLD JOURNAL OF GASTROENTEROLOGY   影响因子和分区

1007-9327

2219-2840

["BACKGROUND Human immunodeficiency virus (HIV)-positive patients coinfected with hepatitis B virus (HBV) are eligible for liver transplantation (LT) in Africa and Southeast Asia, particularly China. However, the outcome of HIV-HBV coinfected patients referred for ABO-incompatible LT (ABOi-LT) is unknown. AIM To clarify the outcome of ABOi-LT for HIV-HBV coinfected patients with end-stage liver disease (ESLD).","METHODS We report on two Chinese HIV- HBV coinfected patients with ESLD who underwent A to O brain-dead donor LT and reviewed the literature on HIV-HBV coinfected patients treated with ABO-compatible LT. The pretransplantation HIV viral load was undetectable, with no active opportunistic infections. Induction therapy consisted of two sessions of plasmapheresis and a single dose of rituximab in two split doses, followed by an intraoperative regimen of intravenous immunoglobulin, methylprednisolone, and basiliximab. Post-transplant maintenance immunosuppressive agents consisted of tacrolimus and mycophenolate mofetil, and prednisone.","RESULTS At the intermediate-term follow-up, patients showed undetectable HIV viral load, CD4(+) T cell counts greater than 150 cells/mu L, no HBV recurrence, and stable liver function. A liver allograft biopsy showed no evidence of acute cellular rejection. Both patients survived at 36-42 mo of follow-up.","CONCLUSION This is the first report of ABOi-LT in HIV- HBV recipients with good intermediate-term outcomes, suggesting that ABOi-LT may be feasible and safe for HIV-HBV coinfected patients with ESLD."]

ABO incompatibility liver transplantation Human immunodeficiency virus Hepatitis B virus End-stage liver disease Immunosuppression

SCI

英语

第一 ; 通讯

Third People's Hospital of Shenzhen Scientific Research Project["G2021008","G2022008"] ; Shenzhen Key Medical Discipline Construction Fund[SZXK079] ; Shenzhen Science and Technology Research and Development Fund["JCYJ20210324131809027","JCYJ20220530163011026"]

Gastroenterology & Hepatology

Gastroenterology & Hepatology

WOS:000973757200007

BAISHIDENG PUBLISHING GROUP INC

CLINICAL MEDICINE

Web of Science

1.Southern Univ Sci & Technol, Peoples Hosp Shenzhen 3, Affiliated Hosp 2, Dept Liver Surg, Shenzhen 518000, Guangdong, Peoples R China
2.Southern Univ Sci & Technol, Peoples Hosp Shenzhen 3, The Affiliated Hosp 2, Organ Transplantat Ctr, Shenzhen 518000, Guangdong, Peoples R China
3.Southern Univ Sci & Technol, Peoples Hosp Shenzhen 3, The Affiliated Hosp 2, Dept Neurol, Shenzhen 518000, Guangdong, Peoples R China
4.Natl Clin Res Ctr Infect Dis, Dept Liver Surg, Shenzhen 518000, Guangdong, Peoples R China
5.Natl Clin Res Ctr Infect Dis, Organ Transplantat Ctr, Shenzhen 518000, Guangdong, Peoples R China
6.Third Peoples Hosp Shenzhen, Dept Liver Surg, 29 Bulan Rd, Shenzhen 518000, Guangdong, Peoples R China
7.Third Peoples Hosp Shenzhen, Organ Transplantat Ctr, 29 Bulan Rd, Shenzhen 518000, Guangdong, Peoples R China

Tang, Jian-Xin,Zhang, Kang-Jun,Fang, Tai-Shi,et al. Outcomes of ABO-incompatible liver transplantation in end-stage liver disease patients co-infected with hepatitis B and human immunodeficiency virus[J]. WORLD JOURNAL OF GASTROENTEROLOGY,2023,29(11).

Tang, Jian-Xin.,Zhang, Kang-Jun.,Fang, Tai-Shi.,Weng, Rui-Hui.,Liang, Zi-Ming.,...&Zhao, Dong.(2023).Outcomes of ABO-incompatible liver transplantation in end-stage liver disease patients co-infected with hepatitis B and human immunodeficiency virus.WORLD JOURNAL OF GASTROENTEROLOGY,29(11).

Tang, Jian-Xin,et al."Outcomes of ABO-incompatible liver transplantation in end-stage liver disease patients co-infected with hepatitis B and human immunodeficiency virus".WORLD JOURNAL OF GASTROENTEROLOGY 29.11(2023).